Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded to Strong-Buy at Cantor Fitzgerald

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They issued an “overweight” rating for the company.

Zealand Pharma A/S Stock Up 2.1 %

Shares of ZLDPF opened at $102.98 on Tuesday. The company has a 50-day simple moving average of $102.26 and a 200-day simple moving average of $117.80. The firm has a market capitalization of $7.31 billion, a P/E ratio of -42.38 and a beta of 0.89. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. Zealand Pharma A/S has a 52 week low of $65.26 and a 52 week high of $141.74.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.